semaglutide cardiovascular outcomes news today 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Cardiovascular Disease | Ozempic® (semaglutide)
Description
Appetite changes may occur within the first few weeks of starting oral semaglutide
For readers who want more context on GLP-1-based treatment, What is GLP-1 Therapy and How Can It Transform Your Weight Loss Journey
Jerlhag et
Ian Lost 40 lbs in Just 4 Months
[8] [9] Comorbidities and concomitant medicines : Patients with type 2 diabetes particularly those taking insulin or sulfonylureas should discuss timing with their clinical team, as reduced appetite following injection may increase the risk of hypoglycaemia and may require dose adjustment of those medicines
